Real-World Postmarketing Study of the Impact of Adalimumab Treatment on Work Productivity and Activity Impairment in Patients with Psoriatic Arthritis

ConclusionAdalimumab treatment improved WPAI in patients with PsA. Improvements in OWI and joint symptoms were significantly associated.Trial Registration NumberClinicalTrials.gov identifier: NCT02414633.FundingAbbVie GK and Eisai Co., Ltd.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research